Intravenous γ-globulin use in children with Kawasaki disease

S. A. Plotkin, R. S. Daum, G. S. Giebink, C. B. Hall, M. Lepow, E. K. Marcuse, G. H. McCracken, C. F. Phillips, G. B. Scott, H. T. Wright, G. Peter, A. R. Hinman, P. Parkman, R. Gold, J. G. Easton

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


A recent controlled American trial of treatment for Kawasaki disease compared the use of acetylsalicylic acid (aspirin) alone v aspirin at the same dose plus a single preparation of IV γ-globulin, which is not currently licensed in the United States. The dosage of IV γ-globulin was 400 mg/kg/d for four days, and the dosage of aspirin was 80 to 100 mg/kg/d for as many as 8 weeks. The results indicated that, if administered within ten days of onset of fever, the combined treatment significantly lowered the prevalence of coronary artery dilation and aneurysms detected at 2 and 7 weeks postenrollment. The IV γ-globulin-treated group showed significant and rapid reduction in fever, WBC count, and generalized inflammatory signs. Prior studies in Japan also showed benefit from IV γ-globulin.

Original languageEnglish (US)
Pages (from-to)122
Number of pages1
Issue number1
StatePublished - 1988

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Intravenous γ-globulin use in children with Kawasaki disease'. Together they form a unique fingerprint.

Cite this